Table 1. Baseline depression and effect on 6 month response and drug survival
| ND | D | CM* | |
|---|---|---|---|
| Subjects (n) | 7292 | 967 | 640 |
| Age ± SD | 57±12 | 56±11 | 56±12 |
| Gender, % female | 76 | 81 | 84 |
| Co-morbidities, n (%) | |||
| 0 | 3953 (53) | 501 (52) | 291 (45) |
| 1 | 2311 (32) | 314 (32) | 225 (35) |
| 2 | 785 (11) | 117 (12) | 79 (12) |
| 3 | 196 (3) | 28 (3) | 39 (6) |
| 4+ | 47 (1) | 7 (1) | 6 (1) |
| DAS28 score, mean ± SD | 6.5±1.0 | 6.6±0.9 | 6.6±1.0 |
| HAQ score, mean ± SD | 2.0±0.6 | 2.1±0.5 | 2.1±0.5 |
| Adjusted OR DAS response (95% CI)** | ref | 1.03[0.85,1.25] | 0.90[0.73,1.13] |
| Adjusted OR HAQ** | ref | 0.79[0.68,0.92] | 0.74[0.62,0.89] |
| Adjusted HR discontinuation of 1st anti-TNF** | ref | 1.01[0.92,1.12] | 1.00[0.88,1.13] |